Emerging Perspectives on Breast Cancer and Antibody–Drug Conjugates Treatment: From Bench to Bedside
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 1327
Special Issue Editor
2. Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy
Interests: breast cancer; treatment
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In recent years, the therapeutic landscape of breast cancer has transitioned from broad-spectrum chemotherapies to precision-targeted treatments, rendering the path to optimizing patient outcomes increasingly complex. In this dynamically evolving scenario, antibody–drug conjugates (ADCs) stand out as a pioneering treatment strategy, promising a transformation in breast cancer care.
ADCs embody the epitome of oncological innovation. Their innovative design, characterized by targeted drug delivery, offers a novel paradigm in cancer therapeutics. By merging the selectivity of targeted therapies with the powerful cytotoxic effects of chemotherapy, ADCs not only minimize systemic toxicity, but also offer broad efficacy, even among patients with a low expression of target antigens.
Currently, three ADCs have gained approval for breast cancer treatment, each targeting distinct antigens and exhibiting remarkable efficacy. Although ADCs are likely to replace traditional agents in the breast cancer therapeutic arsenal, several challenges still persist. Ongoing research is exploring new therapeutic targets, bispecific ADCs, dual-payload ADCs and the potential synergistic interaction between ADCs and other agents, such as immune checkpoint inhibitors.
This Special Issue, entitled "Emerging Perspectives on Breast Cancer and Antibody-Drug Conjugates Treatment: from Bench to Bedside", aims to explore the depths of knowledge surrounding ADCs in the preclinical and clinical arena. We welcome the submission of insightful research articles and reviews that delve into mechanisms of action, biomarker identification, and toxicity management, and those that aim to unravel resistance patterns and strategize treatment pathways. Our aim is to present a comprehensive overview of the field while promoting a more profound and holistic understanding of the topic.
Dr. Alberto Zambelli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- antibody–drug conjugates (ADCs)
- mechanisms of action
- biomarkers identification
- toxicity management
- resistance mechanisms
- treatment sequence
